Pharmaceutical Processing – 2019 outlook
Companies that have been slow in their preparations will need to abandon the idea of customisation and stick to standardised solutions.
The European Falsified Medicines Directive (EU FMD) comes into effect in February 2019, only three months away. For such a logistically and financially demanding task, many contract manufacturing organisations (CMOs) will have anticipated needing a much longer transition period and begun preparations months ago. However, not all are so suitably prepared.
Erik Haeffler spoke to Pharmaceutical Processing on the looming deadline and what this means for CMOs. Alongside other industry experts, he offers advice on how to achieve a smooth transition to companies that have not yet completed preparations.
For full article see: https://www.rdmag.com/article/2018/10/outlook-2019-tech-data-and-biotech-boom